| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MTERFD3 |
| Uniprot No | Q49AM1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 36-385 aa |
| 活性数据 | TTDKQ SSKENTRTVE KLYKCSVDIR KIRRLKGWVL LEDETYVEEI ANILQELGAD ETAVASILER CPEAIVCSPT AVNTQRKLWQ LVCKNEEELI KLIEQFPESF FTIKDQENQK LNVQFFQELG LKNVVISRLL TAAPNVFHNP VEKNKQMVRI LQESYLDVGG SEANMKVWLL KLLSQNPFIL LNSPTAIKET LEFLQEQGFT SFEILQLLSK LKGFLFQLCP RSIQNSISFS KNAFKCTDHD LKQLVLKCPA LLYYSVPVLE ERMQGLLREG ISIAQIRETP MVLELTPQIV QYRIRKLNSS GYRIKDGHLA NLNGSKKEFE ANFGKIQAKK VRPLFNPVAP LNVEE |
| 分子量 | 44.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MTERFD3蛋白的3篇文献示例：
1. **文献名称**：*Structural and functional characterization of human MTERFD3 in mitochondrial transcription regulation*
**作者**：Chen, L. et al.
**摘要**：本研究解析了重组表达的人源MTERFD3蛋白的晶体结构，发现其通过保守的MTERF结构域与线粒体DNA结合，调控16S rRNA的转录终止，并验证了其在HeLa细胞中对线粒体氧化磷酸化活性的影响。
2. **文献名称**：*MTERFD3 interacts with mitochondrial ribosomal proteins and modulates translation fidelity*
**作者**：Garcia, S. & Patel, R.
**摘要**：通过免疫共沉淀和蛋白质组学分析，发现重组MTERFD3与线粒体核糖体亚基相互作用，调控mRNA翻译的准确性;敲低MTERFD3导致活性氧(ROS)累积和细胞凋亡增加。
3. **文献名称**：*Role of MTERFD3 in cancer metabolism: Implications for tumor progression*
**作者**：Wang, Y. et al.
**摘要**：在乳腺癌模型中，MTERFD3过表达通过增强线粒体呼吸链复合体活性促进细胞增殖;重组蛋白体外实验证实其直接结合ATP合酶mRNA，调控能量代谢通路。
(注：以上文献为模拟示例，实际研究需查询具体数据库。)
MTERFD3. a member of the mitochondrial transcription termination factor (MTERF) protein family, plays a role in mitochondrial gene regulation. The MTERF family is primarily associated with transcription termination, ribosomal biogenesis, and translation in mitochondria. MTERFD3. encoded by the nuclear gene *MTERFD3*, is localized to the mitochondrial matrix and binds to mitochondrial DNA (mtDNA) through its conserved MTERF domain. Structural studies suggest it adopts a helical architecture, facilitating interactions with nucleic acids. While its exact mechanism remains under investigation, MTERFD3 is proposed to regulate transcription termination or modulate mtDNA replication by resolving secondary structures or protecting specific regions.
Recombinant human MTERFD3 protein is engineered via heterologous expression systems (e.g., *E. coli* or mammalian cells) and purified using affinity tags (e.g., His-tag). Its recombinant form enables functional studies, including DNA-binding assays, interaction mapping, and structural analysis. Research links MTERFD3 dysregulation to mitochondrial disorders, metabolic diseases, and cancer, highlighting its role in maintaining mitochondrial homeostasis. Current investigations focus on clarifying its interplay with mitochondrial transcription machinery (e.g., POLRMT, TFAM) and its contribution to oxidative phosphorylation. Further studies may uncover therapeutic targets for mitochondrial dysfunction-related pathologies.
×
